surmount-1 tirzepatide non-diabetic weight loss For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The SURPASS to SURMOUNT: The Tirzepatide

Physician-Led, On-Site Care: Patients receive Tirzepatide therapy in a physician-directed medspa where in-person assessments, dose adjustments, and supportive lifestyle guidance are provided by medically trained clinicians

[2] [3] The GIP component appears to complement GLP-1 activity by reducing food intake, while also potentially improving insulin sensitivity in peripheral tissues

And they can support you through the identity shifts that accompany significant weight loss

Dan (board-certified obesity medicine physician) walks through the Ozempic/Wegovy to Mounjaro transition, covering timing, dosing, and what to expect

These side effects are usually mild and diminish as your body adjusts to the treatment

Patients with a history of severe gastrointestinal disease, pancreatitis, or medullary thyroid carcinoma should avoid this treatment